The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials.
E. J. Small
No relevant relationships to disclose
C. S. Higano
Consultant or Advisory Role - Dendreon
P. W. Kantoff
Consultant or Advisory Role - Dendreon (U)
J. B. Whitmore
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
M. W. Frohlich
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
D. P. Petrylak
Consultant or Advisory Role - Dendreon